Nepal, G.; Khurana, M.; Bucheli, D.H.; Bhandari, S.; Joshi, U.; Bhagat, R.; Rehrig, J.H.; Pudasainee, P.; Shing, Y.K.; Ortiz, J.F.;
et al. Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review. Neurol. Int. 2022, 14, 99-108.
https://doi.org/10.3390/neurolint14010009
AMA Style
Nepal G, Khurana M, Bucheli DH, Bhandari S, Joshi U, Bhagat R, Rehrig JH, Pudasainee P, Shing YK, Ortiz JF,
et al. Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review. Neurology International. 2022; 14(1):99-108.
https://doi.org/10.3390/neurolint14010009
Chicago/Turabian Style
Nepal, Gaurav, Mahika Khurana, Domenica Herrera Bucheli, Siddhartha Bhandari, Utsav Joshi, Riwaj Bhagat, Jessica Holly Rehrig, Prasun Pudasainee, Yow Ka Shing, Juan Fernando Ortiz,
and et al. 2022. "Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review" Neurology International 14, no. 1: 99-108.
https://doi.org/10.3390/neurolint14010009
APA Style
Nepal, G., Khurana, M., Bucheli, D. H., Bhandari, S., Joshi, U., Bhagat, R., Rehrig, J. H., Pudasainee, P., Shing, Y. K., Ortiz, J. F., Ojha, R., Gajurel, B. P., Quinonez, J., Ruxmohan, S., Albert, T., Licata, S., & Stien, J.
(2022). Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review. Neurology International, 14(1), 99-108.
https://doi.org/10.3390/neurolint14010009
